4-(2-Methanesulfonylethyl)aniline → N5-{2-[4-(2-Methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1,N5-dimethyl-N2-(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine hydrochloride

Participants

Reaction Steps

The title compound was prepared following the procedure of example one with N5-(2-Chloro-pyrimidin-4-yl)-1,N5-dimethyl-N2-(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine (98 mg, 0.25 mmol) and 4-(2-methanesulfonyl-ethyl)-phenylamine (50 mg, 0.25 mmol) as a white solid (104 mg, 70%). 1H NMR (300 MHz, d6-DMSO+NaHCO3) δ 9.05 (s, 1H), 7.70-7.75 (m, 3H), 7.36 (t, J=5.7 Hz, 1H), 7.20-7.29 (m, 3H), 7.07-7.14 (M, 5H), 6.82 (dd, J=8.1 and 1.5 H. 1H), 5.60 (d, J=5.7 Hz, 1H), 4.54 (d, J=5.4 Hz, 2H), 3.57 (s, 3H), 3.42 (s, 3H), 3.30-3.37 (M, 2H), 2.90-2.95 (m, 5H), 2.26 (s, 3H). MS (ESI) m/z=556 [M+H].

Provenance & Evidence